Press Room

IPAC-RS FDA Roundtable

Start
Monday, November 02, 2020 - 10:30
End
Monday, November 02, 2020 - 10:30
Location: online
IPAC-RS Logo | Hovione

 

 

On November 2, 2020, (10:30 AM – 12:00 PM US ET) IPAC-RS is hosting a webinar with FDAA Conversation with the FDA: Perspectives in the Time of COVID-19. Carla Vozone, Vice President, Pharmaceutical Development & Licensing at Hovione is a panelist in this discussion.

 

Click Here to Register Now

 

 

The IPAC-RS Regulatory Roundtable Series is focused on bringing together leaders in the Orally Inhaled and Nasal Drug Product (OINDP) space. Invited guests will include regulators, industry thought leaders, business leaders, academics, patient groups and others who comprise the OINDP “ecosystem.”

PANELISTS

  • Richard Lostritto, Associate Director for Science in Office of Policy for Pharmaceutical Quality  (OPPQ)/OPQ/CDER/US Food and Drug Administration
  • Brian J. Hasselbalch, Deputy Director, OPPQ/OPQ/CDER/US Food and Drug Administration
  • Carla Vozone, Vice President, Pharmaceutical Development & Licensing, Hovione
  • Martin J. Oliver, Senior Vice President, Generic Programmes, Vectura Ltd.

MODERATOR

  • Mary Devlin Capizzi, IPAC-RS Secretariat and Legal Counsel; Partner, Faegre Drinker Biddle & Reath LLC

 

Click Here to Register Now

 

 

Registration is required to attend the webinar

After registering, individuals will receive a confirmation email containing a custom link* and additional information about joining the webinar.

 

Questions?

Please contact Mrs. Dede Godstrey at the IPAC-RS Secretariat at Dede.Godstrey@FaegreDrinker.com 

 

 

 

Click here to view Webinar Roundtable Flyer

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026